Effect of adding HD-tDCS to regular treatment on social cognition in schizophrenia and its correlation with blood levels of oxytocin

Adjuvant HD-tDCS for social cognition in schizophrenia and its correlation with serum oxytocin: A randomised sham controlled study - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056169

Enrollment

Registered

2023-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F202- Catatonic schizophrenia Health Condition 2: F201- Disorganized schizophrenia Health Condition 3: F208- Other schizophrenia Health Condition 4: F200- Paranoid schizophrenia Health Condition 5: F205- Residual schizophrenia Health Condition 6: F209- Schizophrenia, unspecified Health Condition 7: F203- Undifferentiated schizophrenia

Interventions

Intervention1: High definition transcranial direct current stimulation: The central stimulating anodal electrode will be placed over the left Superior Temporal Sulcus(T3) which will be surrounded by f

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International Classification of Disease-11th edition (ICD-11, World Health Organization,1993) 2. Males aged between 18- 60 years 3. Illness duration of equal to or more than 2 years. 4. Patients giving written informed consent. 5. Right handed. 6. The Positive and Negative Syndrome Scale for Schizophrenia (PANSS), positive score less than 11. 7. Calgary Depression Scale for Schizophrenia (CDSS) score less than7.

Exclusion criteria

Exclusion criteria: 1. Co-morbid neurological or any other medical or psychiatric disorder 2. History of substance abuse(except nicotine and caffeine) 3. History of epilepsy, significant head injury or any other neurosurgical procedures 4. Patients who have received electroconvulsive therapy or neuromodulation techniques in the past one month 5. Having any metallic implants in body

Design outcomes

Primary

Measure	Time frame
Impact on social cognition after application of HD-tDCSTimepoint: Social cognition at baseline & 04 weeks after HDtDCS treatment	—

Secondary

Measure	Time frame
Change in serum oxytocin from baseline to post treatmentTimepoint: Serum oxytocin levels at baseline & 04 weeks after HDtDCS treatment	—

Countries

India

Contacts

Public ContactDr Sunil Kumar R Suryavanshi

Central Institute of Psychiatry

sunilsuryavanshi5@gmail.com8007774822

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026